You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

248 Results
Document
Jul 2022
Guidelines and Advice
Status: Current
ID: GL 2-33
Version: 2
Updated
Jun 2025
Document
Nov 2022
Document
Nov 2022
.
Les fournisseurs de soins de santé trouveront ici des renseignements et des ressources de pratiques exemplaires au sujet des types de dépistage...
Document
Jun 2023
Document
Aug 2023
Document
Sep 2023
Document
Sep 2023
Statistical Reports
Jan 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    zanubrutinib - For the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; and for the treatment of adult patients with previously untreated CLL.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zanubrutinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024

Pages